ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

Provides updated data on prolonged duration of complete response in BCG-Unresponsive and BCG-Naïve NMIBC patients



Following the Type A Meeting with the FDA, ImmunityBio has completed the BLA...

Related Keywords

Massachusetts ,United States , ,Nasdaq ,Exchange Commission ,Health Authority Or Agency ,Drug Administration ,Massachusetts Medical Society ,Immunitybio Inc ,Company Form ,Biologics License Application ,Bacillus Calmette Gu ,Health Authority ,Unresponsive Non ,Muscle Invasive Bladder ,Massachusetts Medical ,Long Term Clinical Outcomes ,Pivotal Trial ,Papillary Non Muscle Invasive Bladder Cancer ,Unresponsive Non Muscle Invasive Bladder Cancer ,Exceptional Responder ,Nonmuscle Invasive Bladder Cancer ,Case Series ,Private Securities Litigation Reform Act ,Complete Response Letter ,Markets ,